Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a clinical-stage biotechnology company advancing targeted therapies for cancer treatment, with a focus on immuno-oncology and precision medicine. This page provides investors and industry stakeholders with timely updates on the company’s clinical trials, strategic collaborations, and regulatory milestones.
Access curated press releases and news articles covering Curis’s pipeline developments, including its lead candidate emavusertib, partnership updates with Aurigene and Genentech, and financial performance. The resource is designed to help users track progress across hematologic and solid tumor indications while staying informed about licensing agreements and scientific advancements.
Content spans clinical trial results, FDA designations, earnings reports, and research publications. Bookmark this page for direct access to verified updates on Curis’s innovative approaches to modulating cancer pathways and expanding treatment options.
Curis, Inc. (NASDAQ: CRIS) announced on April 1, 2021, the grant of inducement stock options for 167,300 shares to five new employees. The options have a ten-year term, with an exercise price equal to the closing stock price on the grant date. Vesting occurs over four years, starting with 25% after one year. This grant is meant to incentivize new hires and is categorized as an inducement award outside the company’s existing stock plan. Curis focuses on cancer therapeutics and has collaborations with various partners for drug development.
Curis, a biotechnology company focused on cancer therapeutics, announced that CEO James Dentzer will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 10:15 am ET. A live webcast will be available on the company's website, with a replay accessible for 90 days. Curis has ongoing collaborations in immuno-oncology, including testing CA-4948 in lymphomas and leukemia, and developing CI-8993 for solid tumors. The company also collaborates with Genentech for Erivedge, a treatment for advanced basal cell carcinoma.
Curis (NASDAQ: CRIS) reported its financial results for Q4 and the year ended December 31, 2020. The company achieved revenues of $10.8 million, up from $10.0 million in 2019. Net loss was $29.9 million, improving from a $32.1 million loss in 2019. Notable developments included positive Phase 1 trial results for CA-4948, showing effectiveness in patients with AML and high-risk MDS. Curis has sufficient cash resources of $183.1 million to support operations into 2024 and looks forward to multiple clinical data readouts throughout 2021.
Curis, Inc. (NASDAQ: CRIS) announced that an abstract for its IRAK4 inhibitor, CA-4948, has been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 10-15, 2021. The presentation, titled Identification of NF-kappaB phospho-p50 as a Potential Predictive Biomarker for IRAK4 inhibitor CA-4948 in Patients with Non-Hodgkin's Lymphoma, falls under the Biomarkers Predictive of Therapeutic Benefit session. CA-4948 is currently in Phase 1 trials for non-Hodgkin's lymphoma and acute myeloid leukemia.
Curis, Inc. (NASDAQ: CRIS) is set to release its fourth quarter 2020 financial results on March 16, 2021, after US market close. A conference call hosted by management will occur at 4:30 pm ET on the same day. Investors can access the call by dialing (888) 346-6389 or (412) 317-5252 internationally. Curis specializes in innovative cancer therapeutics and has collaborations focused on immuno-oncology. Their ongoing studies involve CA-4948 for non-Hodgkin's lymphoma and acute myeloid leukemia, while also collaborating with Genentech on Erivedge® for advanced basal cell carcinoma.
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will present a company overview at the H.C. Wainwright & Co. Global Life Sciences Conference on March 9, 2021. A pre-recorded presentation will be accessible starting at 7:00 am ET. The presentation will be available on-demand on Curis's website under 'Events & Presentations' for about 90 days. Curis specializes in cancer therapeutics, with ongoing trials for treatments targeting various cancers, including non-Hodgkin's lymphoma and acute myeloid leukemia.
Curis, a biotechnology firm specializing in cancer therapeutics, announced that CEO James Dentzer will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, at 1:40 PM ET. A live webcast of the presentation will be accessible on Curis' website, with a replay available for 90 days. Curis is known for its innovative collaborations in immuno-oncology, including exclusive licenses for several small molecule antagonists and kinase inhibitors currently in clinical trials. For further details, visit www.curis.com.
Curis, Inc. (NASDAQ: CRIS) has initiated its Phase 1 trial for CA-4948, a novel IRAK4 kinase inhibitor combined with ibrutinib, targeting relapsed or refractory hematologic malignancies. The trial aims to assess safety, pharmacokinetics, and clinical activity, enrolling approximately 18 patients. Preliminary results from prior studies indicate potential tumor volume reduction with CA-4948. The trial aims to leverage existing clinical sites to expedite progress. However, challenges remain, including the need for further funding and the inherent risks associated with drug development.
Curis, Inc. (CRIS) announced the launch of a Phase 2 trial called LUCAS to evaluate CA-4948, an IRAK4 kinase inhibitor, for anemia treatment in myelodysplastic syndromes (MDS) patients. The trial aims to enroll 84 patients, focusing on efficacy and safety, with recruitment starting in Q2 2021. Positive preliminary data from previous studies supports exploring CA-4948 for lower-risk MDS. The initiative involves collaboration with Dr. Uwe Platzbecker, enhancing Curis' clinical efforts in cancer therapeutics.
Curis, Inc. (NASDAQ: CRIS), a biotech firm specializing in cancer therapeutics, announced that CEO James Dentzer will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 21, 2021, at 11:00 am ET. A live webcast will be available on Curis's website, with a replay accessible for 90 days post-event. Curis collaborates with Aurigene on immuno-oncology and has ongoing trials for oncology treatments including CA-4948 and CI-8993.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
